Press Releases

Our latest news and press releases

Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting

Read more

Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells

Read more

Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00PM PT

Read more

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

Read more

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer

Read more

Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development

Read more

Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy

Read more

Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017

Read more

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Read more

Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting

Read more